These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33410959)

  • 1. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.
    Ostheimer C; Mäurer M; Ebert N; Schmitt D; Krug D; Baumann R; Henkenberens C; Giordano FA; Sautter L; López G; Fleischmann DF; Niyazi M; Käsmann L; Kaul D; Thieme AH; Billiet C; Dobiasch S; Arnold CR; Oertel M; Haussmann J; Gauer T; Goy Y; Suess C; Ziegler S; Panje CM; Baues C; Trommer M; Skripcak T; Medenwald D
    Strahlenther Onkol; 2021 May; 197(5):385-395. PubMed ID: 33410959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.
    In Lee H; Kyung Choi E; Ssan Kim S; Seob Shin Y; Won Park J; Yeol Song S
    Radiother Oncol; 2024 Sep; 198():110383. PubMed ID: 38879129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer.
    Ostheimer C; Schweyer F; Reese T; Bache M; Vordermark D
    Oncol Lett; 2016 Nov; 12(5):3449-3456. PubMed ID: 27900019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study.
    Mäurer M; Käsmann L; Fleischmann DF; Oertel M; Jazmati D; Medenwald D;
    Radiat Oncol; 2022 Feb; 17(1):29. PubMed ID: 35139856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
    Guberina M; Eberhardt W; Stuschke M; Gauler T; Aigner C; Schuler M; Stamatis G; Theegarten D; Jentzen W; Herrmann K; Pöttgen C
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1439-1447. PubMed ID: 30710323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing and validating an integrated gross tumor volume (GTV)-TNM stratification system for supplementing unresectable locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Chen NB; Li QW; Zhu ZF; Wang YM; Cheng ZJ; Hui ZG; Guo SP; He HQ; Wang B; Huang XY; Li JB; Guo JY; Hu N; Ai XL; Zhou Y; Wang DQ; Liu FJ; Xie CM; Qiu B; Liu H
    Radiat Oncol; 2020 Nov; 15(1):260. PubMed ID: 33168045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer.
    Lacoppidan T; Vogelius IR; Pøhl M; Strange M; Persson GF; Nygård L
    Acta Oncol; 2019 Oct; 58(10):1386-1392. PubMed ID: 31271118
    [No Abstract]   [Full Text] [Related]  

  • 9. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
    Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
    Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review.
    Käsmann L; Niyazi M; Blanck O; Baues C; Baumann R; Dobiasch S; Eze C; Fleischmann D; Gauer T; Giordano FA; Goy Y; Hausmann J; Henkenberens C; Kaul D; Klook L; Krug D; Mäurer M; Panje CM; Rosenbrock J; Sautter L; Schmitt D; Süß C; Thieme AH; Trommer-Nestler M; Ziegler S; Ebert N; Medenwald D; Ostheimer C;
    Strahlenther Onkol; 2018 Feb; 194(2):79-90. PubMed ID: 29030654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
    De Petris L; Lax I; Sirzén F; Friesland S
    Med Oncol; 2005; 22(4):375-81. PubMed ID: 16260855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of gross tumor volume in the prognosis of non-small cell lung cancer treated with 3D conformal radiotherapy: a meta-analysis.
    Yu Y; Guan H; Xing LG; Xiang YB
    Clin Ther; 2015 Oct; 37(10):2256-66. PubMed ID: 26293808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer.
    Zhao L; West BT; Hayman JA; Lyons S; Cease K; Kong FM
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):103-10. PubMed ID: 17363189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of gross tumor volume for definitive radiation therapy in patients with locoregionally recurrent non-small-cell lung cancer after surgical resection.
    Lee NK; Moon SH; Kim TH; Han JY; Yun T; Kim HT; Lee HS; Kim MS; Lee JM; Cho KH; Lee JS
    Clin Lung Cancer; 2013 Jul; 14(4):399-406. PubMed ID: 23276823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
    Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
    Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of FDG-PET/CT fused imaging on tumor volume assessment of head-and-neck squamous cell carcinoma: intermethod and interobserver variations.
    Murakami R; Uozumi H; Hirai T; Nishimura R; Katsuragawa S; Shiraishi S; Toya R; Tashiro K; Kawanaka K; Oya N; Tomiguchi S; Yamashita Y
    Acta Radiol; 2008 Jul; 49(6):693-9. PubMed ID: 18568563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Warner A; Dahele M; Hu B; Palma DA; Senan S; Oberije C; Tsujino K; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; De Ruyck K; De Dios NR; Bradley JD; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):612-20. PubMed ID: 26867890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is a higher estimated dose of radiation to immune cells predictive of survival in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy?
    Yin X; Luo J; Xu C; Meng C; Zhang J; Yu H; Liu N; Yuan Z; Wang P; Sun Y; Zhao L
    Radiother Oncol; 2021 Jun; 159():218-223. PubMed ID: 33798612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer?
    Elsayad K; Samhouri L; Scobioala S; Haverkamp U; Eich HT
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1165-1171. PubMed ID: 29623466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.